Alexandria Hammond
Stock Analyst at Wolfe Research
(1.04)
# 3,543
Out of 4,711 analysts
13
Total ratings
33.33%
Success rate
-7.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $701.85 | +63.85% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.36 | -5.16% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $39.39 | +1.55% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $98.05 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly | Initiates: Outperform | $1,000 | $767.76 | +30.25% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $144.47 | +31.52% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $92.57 | +18.83% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $57.33 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $146.47 | - | 1 | Nov 15, 2024 | |
| ABBV AbbVie | Initiates: Outperform | $205 | $175.58 | +16.76% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $30 | $29.34 | +2.25% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $308.44 | -51.37% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $7.94 | +277.83% | 1 | Apr 22, 2024 |
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $701.85
Upside: +63.85%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.36
Upside: -5.16%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $39.39
Upside: +1.55%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $98.05
Upside: -
Eli Lilly
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $767.76
Upside: +30.25%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $144.47
Upside: +31.52%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $92.57
Upside: +18.83%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $57.33
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $146.47
Upside: -
AbbVie
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $175.58
Upside: +16.76%
Apr 22, 2024
Reinstates: Neutral
Price Target: $30
Current: $29.34
Upside: +2.25%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $308.44
Upside: -51.37%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $7.94
Upside: +277.83%